Cost excellence does not mean compromising scientific ambition – it means enabling it.
Smart Sourcing in Pharma R&D
The New Cost
Excellence Imperative
Research & Development (R&D) remains one of the largest and most sensitive cost blocks in the healthcare sector.
Innovation is non-negotiable, yet so are patient safety and scientific rigor. With supplier ecosystems becoming increasingly complex, leading healthcare companies are proving it is possible to manage R&D costs strategically – without compromising on quality, compliance, or the mission to improve patient outcomes.
The R&D cost dilemma: innovation at any price?
Traditionally, R&D in pharma has operated under a unique paradigm: long innovation cycles, uncertain outcomes, and speed often prioritized over cost. However, with tightening funding, intensifying pipeline pressures, and expanding partner networks, R&D expenses are under greater scrutiny.
CFOs and CPOs across the industry are now asking: how can we enable innovation while maintaining cost discipline?
The answer lies not in curtailing science, but in integrating strategic sourcing and governance into R&D. When done right, this accelerates informed decision-making, enhances supplier performance, and supports smart investment.
Procurement’s evolving role in R&D
R&D functions are inherently complex, involving a wide array of specialized services, non-standard cost structures, and external partners. Historically, procurement teams were involved late in the process, often just before contracting –
limiting their ability to influence contract design or commercial outcomes.
This dynamic is shifting. As an example, at one global pharma client, a comprehensive R&D sourcing initiative led to significant cost reductions and performance improvements. The initiative included restructuring the contract research organization (CRO) landscape, consolidating volume across trials, and introducing clear supplier segmentation and commercial models.
By involving sourcing teams earlier in study planning, they ensured better alignment on performance expectations, reduced cost variability, and enhanced transparency around service levels and pricing. The overall outcome was a >15% saving across the addressable CRO spend – achieved without compromising scientific quality or development speed. Importantly, the initiative also created financial headroom to reinvest in innovation and future pipeline activities.
This example reflects a broader industry shift in how companies approach the balance between innovation and cost transparency. Leading organizations are positioning procurement as a strategic partner to clinical and scientific teams – helping shape how supplier partnerships are designed, evaluated, and managed across the development life cycle.
Strategic levers for R&D cost optimization
Across categories like clinical research, regulatory support and lab services, procurement departments are beginning to apply sourcing principles that have long been standard in other business functions. The following levers are helping leading players to control costs while preserving scientific agility:
-
1. Cross-functional governance
Successful R&D sourcing requires alignment across clinical, regulatory, legal, and procurement functions. Joint governance structures like sourcing committees or category councils foster integrated decision-making, improve risk oversight, and enhance supplier performance.
-
2. Supplier strategy and segmentation
A one-size-fits-all approach does not suffice. Differentiating between larger strategic CROs and specialized CROs allows companies to manage each group based on their actual contribution to value. Strategic partners should be engaged in long-term collaborations with shared goals and performance metrics. Having a small group of 2-5 key suppliers and a very limited group of specialized suppliers has become best practice in most cases.
-
3. Demand and scope management
One of the most effective ways to reduce unnecessary cost is to define internal requirements more clearly from the outset. In fast-paced R&D environments, project teams often move quickly into execution with only partial alignment on scope or specifications. By involving sourcing teams early, organizations can harmonize study timelines, avoid redundant service layers, and ensure standardized supplier briefings – a step that enables more competitive pricing and greater consistency across projects. Also in running studies a cost effectiveness can be increased by so-called study value engineering efforts which are mutually interesting for clients as for their strategic CRO partners.
-
4. Commercial model design
Pricing models in R&D sourcing often vary significantly — from milestone-based payments to full-time equivalents, or bundled work packages. Creating consistent commercial frameworks helps to reduce variability, enables fair
comparisons during RFPs, and simplifies contract management. In practice, this means introducing templates that define core pricing structures, aligning payment terms to project milestones, and embedding incentive mechanisms that reward on-time delivery and quality outcomes.
A path forward – and where to go deeper
Together, these four levers form the basis for a scalable, strategic approach to R&D sourcing — one that controls cost without slowing science.
R&D sourcing is on the move. More healthcare companies are beginning to leave behind fragmented, informal procurement practices in favor of more structured, strategic models. This evolution is already delivering visible benefits — from increased cost transparency and improved supplier accountability to faster, more aligned sourcing decisions.
Procurement’s role is evolving accordingly. It is no longer a downstream function brought in to manage budgets. Instead, it is becoming a collaborative partner to R&D — one that enables proactive, value-based choices while supporting patient-focused innovation with the necessary financial discipline and operational structure.
To explore how these levers apply across the different phases of preclinical and clinical development, visit our dedicated R&D sourcing page here.
Authors
Stefan Oprée
Managing Director
is Managing Director at Inverto’s Berlin office and member of the Healthcare practice. He advises pharma clients on cost optimization and procurement transformation.
Cindy Oswald
Principal
is Senior Project Manager at Inverto’s Munich office, specializing in vendor management and strategic sourcing practices within R&D environments.